LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Large GWAS Study Finds DNA Variants Linked to Risk of Developing Breast Cancer

By LabMedica International staff writers
Posted on 13 Jan 2020
Image: Micrograph showing a lymph node invaded by ductal breast cancer and with extranodal extension of the tumor. The dark purple (center) shows lymphocytes (part of a normal lymph node). Surrounding the lymphocytes and extending into the surrounding fat (top of image) is the ductal breast cancer (Photo courtesy of Wikimedia Commons)
Image: Micrograph showing a lymph node invaded by ductal breast cancer and with extranodal extension of the tumor. The dark purple (center) shows lymphocytes (part of a normal lymph node). Surrounding the lymphocytes and extending into the surrounding fat (top of image) is the ductal breast cancer (Photo courtesy of Wikimedia Commons)
A large multinational study identified more than 350 DNA variants associated with the more than 150 regions of the genome known to be linked to the risk for developing breast cancer.

Investigators at more than 450 departments and institutions worldwide, including the University of Cambridge (United Kingdom) and the Wellcome Sanger Institute (Hinxton, United Kingdom), collaborated to compare the DNA of 110,000 breast cancer patients against that of some 90,000 healthy controls.

Previous genome-wide association studies (GWAS), which compared the DNA of patients against that of healthy controls, found around 150 regions of the genome that clearly affected breast cancer risk. The use of advanced gene mapping techniques in the current study enabled investigators to identify 352 risk variants within these regions. So far, it is not yet clear how many genes these variants target, but the investigators have identified 191 genes with reasonable confidence.

In the majority of cases, the variants affected gene expression, how active a particular gene was and how much of a particular protein it created, rather than altering the type of protein coded by the gene. Of the newly-discovered genetic variants, about a third predispose women towards developing hormone-responsive breast cancer, the type of disease found in 80% of breast cancer patients. These tumors respond to hormonal treatments such as tamoxifen. In contrast, 15% of the genetic variants predispose women to the rarer estrogen-receptor-negative type of breast cancer.

"We know from previous studies that variants across our DNA contribute towards breast cancer risk, but only rarely have scientists have been able to identify exactly which genes are involved," said first author Dr. Laura Fachal researcher in human genetics at the Wellcome Sanger Institute. "We need this information as it gives us a better clue to what is driving the disease and hence how we might treat or even prevent it."

"This incredible haul of newly-discovered breast cancer genes provides us with many more genes to work on, most of which have not been studied before," said senior author Dr. Alison Dunning, reader in molecular cancer genetics at the University of Cambridge. "It will help us build up a much more detailed picture of how breast cancer arises and develops. But the sheer number of genes now known to play a role emphasizes how complex the disease is."

The breast cancer genome-wide association study was published in the January 7, 2020, online edition of the journal Nature Genetics

Related Links:
University of Cambridge
Wellcome Sanger Institute


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Alcohol Testing Device
Dräger Alcotest 7000

Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more